The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis
Timothy M Walker,Paolo Miotto,Claudio U Köser,Philip W Fowler,Jeff Knaggs,Zamin Iqbal,Martin Hunt,Leonid Chindelevitch,Maha R Farhat,Daniela Maria Cirillo,Iñaki Comas,James Posey,Shaheed V Omar,Timothy EA Peto,Anita Suresh,Swapna Uplekar,Sacha Laurent,Rebecca E Colman,Carl-Michael Nathanson,Matteo Zignol,Ann Sarah Walker,Derrick W Crook,Nazir Ismail,Timothy C Rodwell,the SeqTreat Consortium CRyPTIC Consortium,A Sarah Walker,Adrie J C Steyn,Ajit Lalvani,Alain Baulard,Alan Christoffels,Alberto Mendoza-Ticona,Alberto Trovato,Alena Skrahina,Alexander S Lachapelle,Alice Brankin,Amy Piatek,Ana Gibertoni Cruz,Anastasia Koch,Andrea Maurizio Cabibbe,Andrea Spitaleri,Angela P Brandao,Angkana Chaiprasert,Anita Suresh,Anna Barbova,Annelies Van Rie,Arash Ghodousi,Arnold Bainomugisa,Ayan Mandal,Aysha Roohi,Babak Javid,Baoli Zhu,Brice Letcher,Camilla Rodrigues,Camus Nimmo,Carl-Michael NATHANSON,Carla Duncan,Christopher Coulter,Christian Utpatel,Chunfa Liu,Clara Grazian,Clare Kong,Claudio U Köser,Daniel J Wilson,Daniela Maria Cirillo,Daniela Matias,Danielle Jorgensen,Danila Zimenkov,Darren Chetty,David AJ Moore,David A Clifton,Derrick W Crook,Dick van Soolingen,Dongxin Liu,Donna Kohlerschmidt,Draurio Barreira,Dumisani Ngcamu,Elias David Santos Lazaro,Ellis Kelly,Emanuele Borroni,Emma Roycroft,Emmanuel Andre,Erik C Böttger,Esther Robinson,Fabrizio Menardo,Flavia F Mendes,Frances B Jamieson,Francesc Coll,George Fu Gao,George W Kasule,Gian Maria Rossolini,Gillian Rodger,E Grace Smith,Graeme Meintjes,Guy Thwaites,Harald Hoffmann,Heidi Albert,Helen Cox,Ian F Laurenson,Iñaki Comas,Irena Arandjelovic,Ivan Barilar,Jaime Robledo,James Millard,James Johnston,Jamie Posey,Jason R Andrews,Jeff Knaggs,Jennifer Gardy,Jennifer Guthrie,Jill Taylor,Jim Werngren,John Metcalfe,Jorge Coronel,Joseph Shea,Joshua Carter,Juliana MW Pinhata,Julianne V Kus,Katharina Todt,Kathryn Holt,Kayzad S Nilgiriwala,Kelen T Ghisi,Kerri M Malone,Kiatichai Faksri,Kimberlee A Musser,Lavania Joseph,Leen Rigouts,Leonid Chindelevitch,Lisa Jarrett,Louis Grandjean,Lucilaine Ferrazoli,Mabel Rodrigues,Maha Farhat,Marco Schito,Margaret M Fitzgibbon,Marguerite Massinga Loembé,Maria Wijkander,Marie Ballif,Marie-Sylvianne Rabodoarivelo,Marina Mihalic,Mark WILCOX,Martin Hunt,Matteo ZIGNOL,Matthias Merker,Matthias Egger,Max O'Donnell,Maxine Caws,Mei-Hua Wu,Michael G Whitfield,Michael Inouye,Mikael Mansjö,Minh Ha Dang Thi,Moses Joloba,SM Mostofa Kamal,Nana Okozi,Nazir ISMAIL,Nerges Mistry,Nhung N Hoang,Niaina Rakotosamimanana,Nicholas I Paton,Paola M V Rancoita,Paolo Miotto,Pascal Lapierre,Patricia J Hall,Patrick Tang,Pauline Claxton,Penelope Wintringer,Peter M Keller,Phan Vuong Khac Thai,Philip W Fowler,Philip Supply,Prapaporn Srilohasin,Prapat Suriyaphol,Priti Rathod,Priti Kambli,Ramona Groenheit,Rebecca E Colman,Rick Twee-Hee Ong,Robin M Warren,Robert J Wilkinson,Roland Diel,Rosangela S Oliveira,Rukhsar Khot,Ruwen Jou,Sabira Tahseen,Sacha Laurent,Saheer Gharbia,Samaneh Kouchaki,Sanchi Shah,Sara Plesnik,Sarah G Earle,Sarah Dunstan,Sarah J Hoosdally,Satoshi Mitarai,Sebastien Gagneux,Shaheed V Omar,Shen-Yuan Yao,Simon Grandjean Lapierre,Simone Battaglia,Stefan Niemann,Sushil Pandey,Swapna Uplekar,Tanya A Halse,Ted Cohen,Teresa Cortes,Therdsak Prammananan,Thomas A Kohl,Nguyen T T Thuong,Tik Ying Teo,Timothy E A Peto,Timothy C Rodwell,Timothy William,Timothy M Walker,Thomas R Rogers,Utkarsha Surve,Vanessa Mathys,Victoria Furió,Victoria Cook,Srinivasan Vijay,Vincent Escuyer,Viola Dreyer,Vitali Sintchenko,Vonthanak Saphonn,Walter Solano,Wan-Hsuan Lin,Wayne van Gemert,Wencong He,Yang Yang,Yanlin Zhao,Youwen Qin,Yu-Xin Xiao,Zahra Hasan,Zamin Iqbal,Zully M Puyen
DOI: https://doi.org/10.1016/s2666-5247(21)00301-3
IF: 86.208
2022-04-01
The Lancet Microbe
Abstract:Background: Molecular diagnostics are considered the most promising route to achieving rapid, universal drug susceptibility testing for <i>Mycobacterium tuberculosis</i>complex (MTBC). We aimed to generate a WHO endorsed catalogue of mutations to serve as a global standard for interpreting molecular information for drug resistance prediction.Methods: A candidate gene approach was used to identify mutations as associated with resistance, or consistent with susceptibility, for 13 WHO endorsed anti-tuberculosis drugs. 38,215 MTBC isolates with paired whole-genome sequencing and phenotypic drug susceptibility testing data were amassed from 45 countries. For each mutation, a contingency table of binary phenotypes and presence or absence of the mutation computed positive predictive value, and Fisher's exact tests generated odds ratios and Benjamini-Hochberg corrected p-values. Mutations were graded as Associated with Resistance if present in at least 5 isolates, if the odds ratio was >1 with a statistically significant corrected p-value, and if the lower bound of the 95% confidence interval on the positive predictive value for phenotypic resistance was >25%. A series of expert rules were applied for final confidence grading of each mutation.Findings: 15,667 associations were computed for 13,211 unique mutations linked to one or more drugs. 1,149/15,667 (7·3%) mutations were classified as associated with phenotypic resistance and 107/15,667 (0·7%) were deemed consistent with susceptibility. For rifampicin, isoniazid, ethambutol, fluoroquinolones, and streptomycin, the mutations' pooled sensitivity was >80%. Specificity was over 95% for all drugs except ethionamide (91·4%), moxifloxacin (91·6%) and ethambutol (93·3%). Only two resistance mutations were classified for bedaquiline, delamanid, clofazimine, and linezolid as prevalence of phenotypic resistance was low for these drugs.Interpretation: This first WHO endorsed catalogue of molecular targets for MTBC drug susceptibility testing provides a global standard for resistance interpretation. Its existence should encourage the implementation of molecular diagnostics by National Tuberculosis Programmes.Funding: UNITAID, Wellcome, MRC, BMGF.
medicine, general & internal